Clinical Trial Update: Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) [Phase 2]

View source ↗

Summary

Phase 2 trial update on nilotinib as first-line treatment for Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-09-01